Clinical trials

One of the goals of the Strategy for Patient-Oriented Research (SPOR) is to strengthen organizational, regulatory and financial support for clinical studies in Canada and enhance patient and clinician engagement in these studies. To help reach this goal, the following initiatives have been implemented:

Innovative Clinical Trials Initiative

As part of its commitment to supporting clinical research and strengthening the environment for clinical trials in Canada, CIHR is investing in an initiative that focuses on the development and implementation of innovative methods in clinical research. The SPOR innovative Clinical Trials (iCT) Initiative will contribute to increasing Canadian competitiveness in iCT research and provide a stimulus for trialists to adopt new methodologies.

The initiative consists of several opportunities. For more information, please consult the Innovative Clinical Trials Initiative page.

Rewarding Success Initiative

To change the paradigm of how research is rewarded, CIHR designed a new funding model that will reward success as a means of incentivizing research teams and their healthcare partners to enhance value-based care, health system sustainability, and health outcomes. Teams will take advantage of innovative clinical trial (iCT) designs to institute complex interventions that will allow them to fail fast and iterate to improve the likelihood of success. Use of an iCT design will also enable unambiguous attribution of the effect of the intervention(s) employed to improve value and efficiency in health care.

For more information, please consult the Rewarding Success Initiative page.

Canadian Clinical Trials Coordinating Centre

The Canadian Clinical Trials Coordinating Centre (CCTCC) was established in 2014 as part of the recommendations from the 2011 Clinical Trials Summit Action Plan [ PDF (277 KB) - external link ] to strengthen the environment for clinical trials in Canada, including the streamlining of processes for companies and researchers, with an aim to regaining Canada’s competitive advantage for hosting clinical trials. It is a unique collaborative effort of the Canadian Institutes of Health Research (CIHR), Innovative Medicines Canada (formerly Canada’s Research-Based Pharmaceutical Companies (Rx&D)), and HealthCareCAN (formerly ACAHO). The CCTCC is housed within the Health Charities Coalition of Canada, in Ottawa.

Canadian Clinical Trials Asset Map

The Canadian Clinical Trials Asset Map (CCTAM) is a unique, robust, searchable web-based database designed to showcase Canada’s clinical research strengths to all stakeholders, including clinical trial sponsors and position Canada as an attractive global destination for the conduct of clinical trials.

Model Clinical Trial Template Agreement

The model Clinical Trial Agreement (mCTA) provides a standard model contract for use by clinical trial sites and sponsors in negotiating phase II and phase III clinical trial agreements.

Streamlining Research Ethics Review for Multi-Centre Trials

Under SPOR, CIHR established the External Advisory Committee on Streamlining Health Research Ethics Review (SHRER) to address Recommendation 4 of the Clinical Trials Summit Action Plan by gathering information on streamlining initiatives in Canada and making recommendations for improving the process of ethics review for multi-centre patient-oriented research.

SHRER Committee’s final recommendations [ PDF (2.48 MB) - external link ]

Date modified: